HK1202334A1 - Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer - Google Patents

Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Info

Publication number
HK1202334A1
HK1202334A1 HK15102817.0A HK15102817A HK1202334A1 HK 1202334 A1 HK1202334 A1 HK 1202334A1 HK 15102817 A HK15102817 A HK 15102817A HK 1202334 A1 HK1202334 A1 HK 1202334A1
Authority
HK
Hong Kong
Prior art keywords
treatment
breast cancer
blood plasma
combination therapies
plasma biomarkers
Prior art date
Application number
HK15102817.0A
Other languages
English (en)
Chinese (zh)
Inventor
Ursula Klause
Nicola Moore
Cline Pallaud
Stefan Scherer
Norbert Wild
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1202334A1 publication Critical patent/HK1202334A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15102817.0A 2012-06-26 2015-03-19 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer HK1202334A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664612P 2012-06-26 2012-06-26
US201261697667P 2012-09-06 2012-09-06
PCT/EP2013/063094 WO2014001232A1 (en) 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
HK1202334A1 true HK1202334A1 (en) 2015-09-25

Family

ID=48672633

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102817.0A HK1202334A1 (en) 2012-06-26 2015-03-19 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Country Status (10)

Country Link
EP (1) EP2864788A1 (xx)
JP (1) JP2015522815A (xx)
KR (1) KR20150024342A (xx)
CN (1) CN104364655A (xx)
BR (1) BR112014032456A2 (xx)
CA (1) CA2871385A1 (xx)
HK (1) HK1202334A1 (xx)
MX (1) MX2014014821A (xx)
RU (1) RU2015102026A (xx)
WO (1) WO2014001232A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594365A4 (en) 2017-03-08 2021-01-06 Industry - University Cooperation Foundation Hanyang University HER2-POSITIVE CANCER BIOMARKER AND ANTI-HER2 TREATMENT AND ITS USE
KR102028703B1 (ko) * 2017-11-21 2019-10-04 한양대학교 산학협력단 유방암의 진단 및 치료를 위한 바이오 마커

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74201A0 (en) 1984-01-30 1985-04-30 Icrf Patents Limited Polypeptides for the detection and control of mammalian cell growth
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
JP3208427B2 (ja) 1989-09-29 2001-09-10 オー・エス・アイ・ファーマシューテイカルズ・インコーポレイテッド ヒトの生物学的流体中のｎｅｕ関連タンパク質の検出及び定量
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
BRPI0817158A2 (pt) * 2007-11-09 2015-04-14 Genentech Inc "método de identificar um paciente com câncer renal, kit, métodos e conjunto de compostos"
US20110045060A1 (en) * 2008-02-29 2011-02-24 Shinshu University Kit for detecting cancer cells metastasizing into sentinel lymph node
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
EP2454380A2 (en) * 2009-07-13 2012-05-23 F. Hoffmann-La Roche AG Diagnostic methods and compositions for treatment of cancer
KR20120059553A (ko) * 2009-08-14 2012-06-08 제넨테크, 인크. Ｖｅｇｆ 길항제에 대한 환자 반응을 모니터링하기 위한 생물학적 마커
MX2012008153A (es) * 2010-01-12 2012-11-06 Nestec Sa Metodos para predecir la respuesta a terapia de cancer de mama triple negativo.
WO2012010548A1 (en) * 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy

Also Published As

Publication number Publication date
CA2871385A1 (en) 2014-01-03
CN104364655A (zh) 2015-02-18
KR20150024342A (ko) 2015-03-06
WO2014001232A1 (en) 2014-01-03
EP2864788A1 (en) 2015-04-29
RU2015102026A (ru) 2016-08-10
JP2015522815A (ja) 2015-08-06
MX2014014821A (es) 2015-02-12
BR112014032456A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
HK1184854A1 (zh) 貝伐單抗組合療法用於治療乳腺癌的血漿生物標誌物
HK1201413A1 (en) Treatment of breast cancer
IL237558A0 (en) Methods for treating locally advanced breast cancer
HK1254859A1 (zh) 治療乳腺癌的方法
ZA201403602B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2788378A4 (en) ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
IL263781A (en) Combined treatment of ovarian cancer
EP2830633A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
HK1181459A1 (zh) 貝伐單抗組合療法用於治療胰腺癌的血漿生物標誌物
HK1214128A1 (zh) 癌症的治療
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
HK1202334A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
GB201217890D0 (en) Treatment of cancer
GB201200262D0 (en) Therapy of breast cancer
IL233495A0 (en) Combination for cancer treatment
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201208296D0 (en) Treatment of cancer